Comment
doi: 10.1186/bcr2134.
Epub 2008 Sep 26.
Luminal B breast tumors are not HER2 positive
- PMID: 18831725
- PMCID: PMC2614503
- DOI: 10.1186/bcr2134
Item in Clipboard
Comment
Luminal B breast tumors are not HER2 positive
Breast Cancer Res.
2008.
No abstract available
Comment on
-
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5. Breast Cancer Res. 2008. PMID: 18681955 Free PMC article.
Similar articles
-
HER2 as a prognostic factor in breast cancer.Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404. Oncology. 2001. PMID: 11694790 Review.
-
[Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].Rev Esp Med Nucl. 2000 Jun;19(3):244-6. Rev Esp Med Nucl. 2000. PMID: 11062090 Spanish. No abstract available.
-
Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.West Indian Med J. 2002 Mar;51(1):4-9. West Indian Med J. 2002. PMID: 12089875
-
Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.J Exp Clin Cancer Res. 1999 Sep;18(3):357-61. J Exp Clin Cancer Res. 1999. PMID: 10606182
-
[Therapeutic targeting in breast cancer].Ann Pathol. 2009 Nov;29 Spec No 1:S71-3. doi: 10.1016/j.annpat.2009.07.047. Epub 2009 Oct 21. Ann Pathol. 2009. PMID: 19887259 Review. French. No abstract available.
Cited by
-
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.Breast Cancer (Auckl). 2012;6:1-8. doi: 10.4137/BCBCR.S8323. Epub 2011 Dec 6. Breast Cancer (Auckl). 2012. PMID: 22259247 Free PMC article.
-
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer.Mol Cancer Ther. 2020 Jan;19(1):3-12. doi: 10.1158/1535-7163.MCT-19-0253. Mol Cancer Ther. 2020. PMID: 31909732 Free PMC article. Review.
-
A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade, Ki67, p53 Overexpression, and DNA Ploidy.Int J Breast Cancer. 2011;2011:217060. doi: 10.4061/2011/217060. Epub 2011 Aug 17. Int J Breast Cancer. 2011. PMID: 22295212 Free PMC article.
-
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.Med Oncol. 2012 Sep;29(3):1536-42. doi: 10.1007/s12032-011-0082-y. Epub 2011 Oct 8. Med Oncol. 2012. PMID: 21983862
-
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.J Cancer Epidemiol. 2014;2014:469251. doi: 10.1155/2014/469251. Epub 2014 May 26. J Cancer Epidemiol. 2014. PMID: 24955090 Free PMC article.
References
-
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. doi: 10.1001/jama.295.21.2492. - DOI - PubMed
-
- Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M van de, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
-
- Sorlie T. Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol. 2007;360:91–114. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
